The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
This maybe a better link
https://www.telegraph.co.uk/news/lockdown-files/
Have 100,000 WhatsApp messages between Han**** and ministers. Today is care homes. They will move onto testing.
Look at the most liked comments . There is a paywall
https://www.telegraph.co.uk/news/2023/02/28/lockdown-files-matt-han****-whatsapp-whitty-care-homes-covid/#comment
This needs putting into simple laymans terms that IIs and the media will take up and publicise.
Avactas PR people and people like Paul Hill need to work together on this.
I said earlier that Paul Hill needs to do an interview with AS….ASAP !
V o x m a r k e t s. Without the gaps
**********
https://www.**********.co.uk/authors/paulhill-1/
We need a Paul Hill interview with AS …….ASAP!
https://www.thearmchairtrader.com/kodal-minerals-secures-funding-lithium-mine-production/
SCIENCE INVESTMENT
Sir, Emma Duncan’s column about problems facing UK life science companies (Jan 27) is right that lack of investment drives pioneering British businesses to turn to the United States for scale-up funding. Despite our world-leading expertise, UK biotech unicorns are rare. In the past four years 11 UK biotechs have chosen to make their initial public offering in the US. Why are we so bad at holding on to long-term value generated by our innovative science? There are many factors but in my view it’s primarily due to overburdensome regulation, compounded by a paucity of expert analysts to guide risk-averse UK investment managers.
The retail distribution review (RDR) and the EU-generated markets in financial instruments directive II (MiFID II) both had dire unintended consequences for high-growth, high-risk companies. These oppressive pieces of regulation put smaller investment banks off high-risk stocks, restricting the UK public markets opportunity for many life sciences companies, giving them little choice but to seek funding abroad.
Jeremy Hunt wants science innovators to come to Britain “to make their visions happen”. Admirable aspiration, but we need a smarter strategy to scale our own life science sector if we’re to reap the potentially substantial rewards. A good start would be relaxing the constraints of RDR and MiFID II.
Dr Alastair Smith
CEO, Avacta Group
As Meyer said, it shows deal is going through and Chinese can be trusted……….
I wrote to Joanne Hart last week. ….”on her radar”
I have commented on the article….as have others. I gave a link to the RNS
RNS sent to This is Money at Daily Mail
Just you dare try and hold this back……….
Followed by a nice cup of Yorkshire tea…….
Surprised so few have responded to this comment. This is the driving force behind todays rise. Now we can sell stock…at a price?
Bad news is put out on Fridays…..specifically so that most journos miss it.
Avactas favourite day is Thursday……to give them something for the weekend……and a share price boost for us on the following Monday.
You really think financial advisers work on a Friday afternoon. Weekend copy is put to bed Thursday pm.
Going well ?
All the best to all here for a rewarding new year.
Can we have a resolution to stop cluttering up the board with having a go at each other?
You know who you are.
Thanks